CT and X-ray contrast agents: Current clinical challenges and the future of contrast
Acta Biomaterialia · 2023-11 · 171 · 19-36
DOI: 10.1016/j.actbio.2023.09.027 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Biomaterialia, 2023-11. Verfasst von Tyler C Owens und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University o…. Hauptthemen laut MEDLINE: Contrast Media, Nanoparticles. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 108 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Computed tomography (CT) is a powerful and widely used imaging technique in modern medicine. However, it often requires the use of contrast agents to visualize structures with similar radiographic density. Unfortunately, current clinical contrast agents (CAs) for CT have remained largely unchanged for decades and come with several significant drawbacks, including serious nephrotoxicity and short circulation half-lives. The next generation of CT radiocontrast agents should strive to be long-circulating, non-toxic, and non-immunogenic. Nanoparticle contrast agents have shown promise in recent years and are likely to comprise the majority of next-generation CT contrast agents. This review highlights the fundamental mechanism and background of X-ray and contrast agents. It also focuses on the challenges associated with current clinical contrast agents and provides a brief overview of potential future agents that are based on various materials such as lipids, polymers, dendrimers, metallic, and non-metallic inorganic nanoparticles (NPs). STATEMENT OF SIGNIFICANCE: We realized a need for clarification on a number of concerns related to the use of iodinated contrast material as debates regarding the safety of these agents with patients with kidney disease, shellfish allergies, and thyroid dysfunction remain ongoing in medical practice. This review was partially inspired by debates witnessed in medical practice regarding outdated misconceptions of contrast material that warrant clarification in translational and clinical arenas. Given that conversation around currently available agents is at somewhat of a high water mark, and nanoparticle research has now reached an unprecedented number of readers, we find that this review is timely and unique in the context of recent discussions in the field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA. Electronic address: ty…
- Université de Strasbourg, INSERM, Regenerative Nanomedicine UMR 1260, Centre de Recherche en Biomédecine de Strasbourg (CRBS), F-67000 Strasbourg, France.
- Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA. Electronic address: ma…
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Owens, T. C., Anton, N., & Attia, M. F. (2023). CT and X-ray contrast agents: Current clinical challenges and the future of contrast. Acta Biomaterialia, 171, 19-36. https://doi.org/10.1016/j.actbio.2023.09.027
Vancouver
Owens TC, Anton N, Attia MF. CT and X-ray contrast agents: Current clinical challenges and the future of contrast. Acta Biomaterialia. 2023;171:19-36. doi:10.1016/j.actbio.2023.09.027
BibTeX
@article{Owens2023,
author = {Owens, Tyler C and Anton, Nicolas and Attia, Mohamed F},
title = {CT and X-ray contrast agents: Current clinical challenges and the future of contrast},
journal = {Acta Biomaterialia},
year = {2023},
volume = {171},
pages = {19--36},
doi = {10.1016/j.actbio.2023.09.027}
}
EUVIMED